Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer
نویسندگان
چکیده
منابع مشابه
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
REFERENCES 1. Lam JS, Shvarts O, Leppert JT, et al: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466-472, 2005 2. Brugarolas J: Renal-cell carcinoma: Molecular pathways and therapies. N Engl J Med 356:185-187, 2007 3. Motzer RJ, Hutson TE, Tomcza...
متن کامل[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
BACKGROUND Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it's the one of molecular targets in clinical treatment. But the EGFR tyrosine kinase inhibitors (TKI)-resistance is becoming a challenging clinical problem as following the application of EGFR-TKIs, Gefitinib or Erlotinib. However, the mechanistic explanation fo...
متن کاملEpithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
INTRODUCTION Mesenchymal status is related to "inherent resistance" to gefitinib or erlotinib in non-small cell lung cancer without epidermal growth factor receptor(EGFR) mutations. In addition, a recent report showed that the epithelial to mesenchymal transition (EMT) plays a role in acquired resistance to gefitinib in A549 cells, which harbor a KRAS mutation. However, recent clinical studies ...
متن کاملEpidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran
Background and Objective: Epidermal growth factor receptor (EGFR) gene mutation, especially in exons 18 to 21, is an important predictor of the response rate of lung adenocarcinoma to tyrosine kinase inhibitors. There are variable reports from Asian and European countries, as well as North America, about the frequency of the EGFR mutation in lung adenocarcinoma, yet molecular s...
متن کاملTitle Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor- activating mutation-positive non-small-cell lung cancer patients
Objective: To compare the effectiveness and costeffectiveness of erlotinib versus gefitinib as first-line treatment of epidermal growth factor receptor– activating mutation-positive non–small-cell lung cancer patients. Design: Indirect treatment comparison and a costeffectiveness assessment.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2015
ISSN: 0008-543X
DOI: 10.1002/cncr.29397